The collaborative study with Tommy’s Charity and St Mary’s NHS Hospital (Manchester, UK) used Yourgene’s IONA® Nx NIPT Workflow, a fully validated clinical workflow which utilises NGS to estimate the trisomy risk in the fetus.

The collaborative study with Tommy’s Charity and St Mary’s NHS Hospital (Manchester, UK) used Yourgene’s IONA® Nx NIPT Workflow, a fully validated clinical workflow which utilises NGS to estimate the trisomy risk in the fetus.

Yourgene announces the reappointment of Dr. Joanne Mason, Chief Scientific Officer, as a Director of the Company with immediate effect.

Yourgene has entered into an agreement via its subsidiary Concepta Diagnostics Limited with Boots UK Limited (“Boots”), the health and beauty retailer and pharmacy group, to launch its extended range of at-home self-testing products tests via boots.com and across 120 Boots stores in Great Britain and Northern Ireland.

Andy Leeser is one of the UK’s most experienced mid-market corporate transformation specialists. He has been involved with a range of transformation projects and transactions, including refinancings and equity/ asset sales across the Automotive, Oil and Gas, Brewing, Retail and Telecommunications sectors.

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Notice of AGM, Change of Registered Address and Investor Presentation Manchester, UK – 25 August 2022: Yourgene (AIM: YGEN), the international molecular diagnostics...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Open Day and advance notice of AGM Manchester, UK – 16 August 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, will be hosting an Open Day at its new facilities on Manchester...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Audited Final Results    Manchester, UK – 27 July 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces its final results for the financial year ended 31 March...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Dr John Brown CBE confirmed as Chairman Manchester, UK – 27 July 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, confirms the appointment of Dr John Brown CBE as Chairman...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Launch of the Accelerator Phase for Microdeletions Plugin Expanding the clinical menu and capabilities of IONA® Nx NIPT Workflow offering Manchester, UK – 24 May 2022: Yourgene (AIM: YGEN), a...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Full year trading update Manchester, UK – 26 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, provides the following unaudited trading update for the year ended 31...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Directorate Change Manchester, UK – 26 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that after a five-year tenure, Adam Reynolds will step down from...

Yourgene Health plc (“Yourgene” or the “Company”) Strategic partnership extended with Ambry Genetics Expanding market access of technology Manchester, UK – 25 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the Company...

Yourgene Health plc (“Yourgene”  or the “Company”) Capital Markets Day Manchester, UK – 6 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it will be holding a Capital Markets Day for investors on Tuesday 26 April...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Successful CTDA desktop review Approval for sale of Clarigene® SARS-CoV-2 Test in the UK Manchester, UK - 17 February 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostic group,...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Directorate Change Manchester, UK - 25 January 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces the appointment of Mary Tavener as a Non-executive Director...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Opening of new Yourgene Health Canada Inc. facilities Supporting future growth for Ranger® Technology Manchester, UK – 19 January 2022: Yourgene (AIM: YGEN), the international molecular diagnostics...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Agreement of new debt facility Silicon Valley Bank facility to provide non-dilutive funding for accretive growth opportunities Manchester, UK – 19 January 2022: Yourgene (AIM: YGEN), a leading...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) US partnership with EKF Diagnostics for NIPT and additional genomic tests Collaboration with EKF Diagnostics to use its accredited US laboratories for NIPT and Oncology testing Manchester, UK – 18...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Current year trading update Further upgrade to full year revenue guidance following strong trading performance Manchester, UK – 17 January 2022: Yourgene (AIM: YGEN), the international molecular...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) DHSC contract awarded to support COVID-19 Winter surge testingThird contract awarded under PHE National Microbiology Framework Agreement Manchester, UK – 23 December 2021: Yourgene (AIM: YGEN), a leading...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) H1 revenues doubled year-on-yearFull year revenues to exceed already upgraded market expectations Manchester, UK – 14 December 2021: Yourgene (AIM: YGEN), a leading integrated technologies and service...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) UKHSA contract awardContract for the provision of the genetic sequencing services Manchester, UK – 14 December 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces...

Yourgene Health plc(“Yourgene” or the “Company”) DPYD screening recommended in SpainFollows recommendations in Germany, Wales, England and Belgium Manchester, UK – 18 November 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, welcomes...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Yourgene’s Ranger® Technology to be presented at Labroots webinar Manchester, UK – 28 October 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that its Ranger®...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Half-year Trading updateImproved H1 and year-to-date performance supporting higher full-year expectations Manchester, UK – 26 October 2021: Yourgene (AIM: YGEN), a leading international molecular...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Further National Microbiology Framework contract award Successful tender under Lot 4 (Clinical Laboratory Diagnostic Testing Services) valued at £15bn Manchester, UK – 19 April 2021: Yourgene (AIM:...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) AGM StatementInvestor presentation Manchester, UK - 28 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, will be holding its Annual General Meeting (AGM)...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Further re: DHSC contract secured to support COVID-19 surge testing Manchester, UK 10 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that a Contract...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Yourgene Genomic Services receive ISO 15189:2012 accreditation Validating its COVID-19 testing and sequencing services, providing assurance of compliance to international standards to deliver quality...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Notice of AGM and Annual Report 2021Investor presentation Manchester, UK 1 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that the Notice of Annual...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Yourgene’s COVID-19 testing investment reaps rewardsDHSC contract secured to support COVID-19 surge testing Manchester, UK 19 August 2021: Yourgene (AIM: YGEN), a leading international molecular...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Audited Final results and unaudited Q1 business update Manchester, UK – 11 August 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces its full year financial results for...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Earn-out Milestone, Issue of Equity & Total Voting Rights Manchester, UK 11 August 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces an issue of equity...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Second Strategic Partner for Coastal Genomics Manchester, UK – 21 June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Health Inc., the Company’s...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Contract Award for the supply of DPYD testing kits to NHS WalesEstimated to be worth £232,000 across two years   Manchester, UK –  June 2021: Yourgene (AIM: YGEN), the international molecular...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Multi-year licence and supply agreement with leading US precision medicine company Manchester, UK – 9 June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces it has...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Distribution Partnership for the Middle East and AfricaYourgene and Alliance Global launch partnership across multiple territories Manchester, UK – 19 May 2021: Yourgene (AIM: YGEN), the international...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Launch of IONA® Care NIPT service offeringExtended clinical menu to screen SCAs and AAs for pregnant women Manchester, UK – 18 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Yourgene Genomic Services to support MHC’s second Boots agreement for Day 2 & Day 8 testingfor international arrivals to the UK  Manchester, UK – 17 May 2021: Yourgene (AIM: YGEN), the...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Full year Trading update10% year-on-year revenue growth Manchester, UK – 29 April 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Further National Microbiology Framework contract awards Successful tenders under Lots 2 & 3 valued at a total of £4bnYourgene one of only three companies to have been successfully awarded under all...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) National Framework contract award for Covid-19 testing products and services Yourgene successful in UK-wide National Microbiology Framework (Lot 1) Manchester, UK – 19 April 2021: Yourgene (AIM: YGEN),...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Testing service agreement with MyHealthChecked plc Yourgene Genomic Services providing COVID-19 services to MHC’s new Boots partnership Manchester, UK – 6 April 2021: Yourgene (AIM: YGEN), the...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) COVID-19 update Approved provider of day two and day eight coronavirus testing for international arrivals, for both PCR and sequencing Manchester, UK – 29 March 2021: Yourgene (AIM: YGEN), the...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Twin Pregnancy study published using Yourgene’s IONA® Test Manchester, UK – 19 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, welcomes the paper published in the...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Appointment of VP of Sales North AmericaStrategic hire to expand Yourgene’s commercial footprint in North America Manchester, UK – 17 March 2021: Yourgene (AIM: YGEN), the international molecular...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Yourgene Genomic Services portfolio expansion Cytox’s genoSCORETM-LAB test can predict the risk of developing Alzheimer’s disease Yourgene Genomic Services to run the array-based test at Citylabs 1.0 in...

Yourgene Health plc ("Yourgene" or the "Group" or the "Company") First US Supply Agreement for Coastal Genomics’ Technology Signed with Major Strategic Partner Manchester, UK – 1 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group,...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Partnership with NPH To provide COVID-19 testing service for Leeds Bradford Airport Manchester, UK – 22 February 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Trading update Strong H2 momentum expected to deliver double-digit annual growth but below expectations Deferred revenue opportunities, investment in offering and further new initiatives expected to...

Yourgene Health plc("Yourgene" or the "Group" or the "Company") DPYD screening recommended in Belgium Manchester, UK – 13 January 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, welcomes the research article published on 11 January 2021, in...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Clarigene® SARS-CoV-2 Product Update and Partnerships with CityDoc and ReCoVa-19 Manchester, UK – 11 January 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) COVID-19 update: approved provider for UK Government and response to new virus strain Manchester, UK – 24 December 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group,...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Half-year Report Manchester, UK – 17 December 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) DPYD kits recommended by NHS England Manchester, UK – 2 December 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, welcomes the Clinical Commissioning Urgent Policy Statement,...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Directorate changeChief Scientific Officer appointment to drive new product development roadmap Manchester, UK – 5 November 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group,...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Partnership with Take2 Health LimitedYourgene to run genomic test for Nasopharyngeal Carcinoma (NPC) Screening in Taiwan Manchester, UK – 3 November 2020: Yourgene (AIM: YGEN), the international...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Half-year Trading updateH1 year-on-year growth demonstrating the resilience of the Company Manchester, UK – 26 October 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group,...

Yourgene Health plc(“Yourgene Health” or the "Company") CQC registration Manchester, UK – 23 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces that it has received notification from the Care Quality Commission...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Yourgene Genomic Services collaboration with Cytox Partnership with Cytox to enable clinical access to genoSCORE™ - a new genetic test to determine the risk of developing Alzheimer’s disease Manchester,...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Medilink Award win for Outstanding Achievement Manchester, UK – 14 February 2020:Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has won the Outstanding...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Elucigene DPYD tests to be used routinely in Wales Wales is first UK nation to offer DPYD screening to patients undergoing chemotherapyDPYD tests screen patients to identify risk of severe side effects...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Strategic reproductive health partnership secured in Japan Manchester, UK – 8 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces it has entered into...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) IONA® Nx awarded contract with St George’s NHS Hospital Manchester, UK – 7 October 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has been awarded the...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) CE-IVD Mark for Clarigene™ SARS-CoV-2 test Manchester, UK – 3 August 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has achieved CE-IVD marking for its...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Launch of Yourgene Genomic Services Manchester, UK – 28 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of Yourgene Genomic Services, an...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) DPD reimbursement in Germany Manchester, UK – 24 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that the German Federal Joint Committee, G-BA, the national...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) AGM Statement Manchester, UK – 22 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, will be holding its Annual General Meeting (AGM) at 4:00pm today. At the meeting,...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) US distribution agreement for DPYD and other products Manchester, UK – 21 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has appointed...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) IONA® Nx Launch Manchester, UK – 3 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of IONA® Nx NIPT workflow, the Company’s new innovative...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) TGA approves IONA® Nx for sale in Australia Manchester, UK – 13 August 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its IONA® Nx NIPT workflow (‘IONA®...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Successful £16.15 million Placing & Close of Accelerated Bookbuild Manchester, UK – 5 August 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group, is pleased to...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Result of Placing Manchester, UK – 5 August 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group, is pleased to confirm, further to the announcements made yesterday...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Proposed Acquisition and Placing to raise a minimum of £13 million Manchester, UK – 4 August 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group, today announces a...

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Yourgene Health plc(“Yourgene”, the “Company” or the “Group”) Final Results Manchester, UK – 28 July 2020: Yourgene Health plc (AIM: YGEN), the international...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) COVID-19 assay launched Launch of Clarigene™ SARS-CoV-2 test (‘RUO’) Manchester, UK – 30 June 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the launch of its...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Collaboration in COVID-19 testing Supporting the effort to get Britain back to work Manchester, UK – 16 June 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) CE-IVD mark received for Illumina-based IONA® testNon-invasive prenatal screening test to launch as IONA® Nx Manchester, UK – 15 June 2020: Yourgene (AIM: YGEN), a leading international molecular...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Yourgene COVID-19 testing service launch and business update Manchester, UK – 26 May 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has expanded its...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Year-end Trading update: Revenues increase 86% Manchester, UK – 20 April 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the year ended 31...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Presentation on ‘Adapting during crisis’ Manchester, UK – 7 April 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces that Hayden Jeffreys, Chief Operating...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Contract manufacturing agreement for COVID-19 diagnostic test Manchester, UK – 25 March 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the signing of an...

THIS ANNOUNCEMENT, INCLUDING THE APPENDICES, AND THE INFORMATION CONTAINED WITHIN THEM, IS RESTRICTED AND IS NOT FOR PUBLIC RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE...

Yourgene Health plc(“Yourgene” or the “Company”) CE Marking Technical File submission Manchester, UK – 17 February 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has submitted its CE Marking Technical File for the...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) TGA approves DPYD for sale in Australia Southern Cross, Yourgene’s Australian distributor, to sell the chemotoxicity diagnostic assay in the Territory Manchester, UK – 14 February 2020:Yourgene (AIM:...

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.  Yourgene Health plc  (“Yourgene”, the “Company” or the “Group”)  Half-year Report  Manchester, UK – 2 December 2019: Yourgene Health plc (AIM:...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Bionow Double Award Wins Manchester, UK – 29 November 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has won Bionow Investment Deal of Year and Bionow...

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Opening of New Facilities and Corporate HQ  Manchester, UK – 28 November 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the official opening of its...

Yourgene Health plc(“Yourgene” or the “Group” or the “Company”) Launch of Yourgene Flex™ Analysis Software Manchester, UK 31 October 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has launched Yourgene Flex™ Analysis...

Yourgene Health plc (“Yourgene” or the “Group”) American Society of Human Genetics Annual Meeting attendance Manchester, UK – 15 October 2019:Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it will be exhibiting at the...

Yourgene Health plc (“Yourgene” or the “Group”) Half year trading update Manchester, UK – 14 October 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, provides a positive trading update for the six months to 30 September 2019....

CE-IVD Certification renewal Manchester, UK – 26 September 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that in preparation for a 2020 product launch and as a contingency for BREXIT, the Company has successfully...

Yourgene Health plc (“Yourgene” or the “Company”) Launch of DPYD chemotoxicity diagnostic assay Test to identify cancer patients at risk of lethal side effects from chemotherapy Manchester, UK – 18 September 2019: Yourgene (AIM: YGEN), a leading international...

Yourgene Health plc (“Yourgene” or the “Company”) Notice of AGM Manchester, UK – 20 August 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that its Annual General Meeting (AGM) will be held at 4:00pm on 17 September 2019 at...

Yourgene Health plc (“Yourgene” or the “Company”) Directorate Change Appointment of business development sector specialist as Non-executive Director  Manchester, UK – 16 August 2019:Yourgene (AIM: YGEN), a leading international molecular diagnostics group,...

Yourgene Health plc (“Yourgene”, the “Company” or the “Group”) Appointment of Director Manchester, UK – 29 July 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces the...

Yourgene Health plc (“Yourgene” or the “Company” or the “Group”) Results for the Year Ended 31 March 2019, Business Update and Director Change  Manchester, UK – 10 July 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which...

Yourgene Health plc(“Yourgene” or the “Company” or the “Group”) Results for the Year Ended 31 March 2019, Business Update and Director Change Manchester, UK – 10 July 2019: Yourgene Health plc (AIM: YGEN), the international...

Yourgene Health plc(“Yourgene Health” or the "Company") Yourgene participates in key global conferences Manchester, UK - 24 June 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services,...

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR PUBLIC RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY...

Yourgene Health plc(“Yourgene” or the “Company”) Proposed acquisition of Delta Diagnostics (UK) Limited ("Elucigene")andProposed placing of a minimum of 92,682,928new Ordinary SharesandProposed subscription for 4,878,048new Ordinary Shares Highlights ● Proposed...

Yourgene Health plc (“Yourgene”, the “Company” or the “Group”) Full-year Trading Update Manchester, UK – 8 April 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces a trading...

Yourgene Health plc (“Yourgene” or the “Company”) Yourgene raises IONA® test awareness in Egypt with British Ambassador Manchester, UK – 25 March 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and...

Yourgene Health plc (“Yourgene” or the “Company”) Yourgene Health Announces Capital and Commercial Restructuring with Major Shareholder Manchester, UK – 18 February 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises...

Yourgene Health plc (“Yourgene”, the “Company”)   Yourgene launches Sage™ 32 plex   High throughput NIPT solution for clinical laboratories   Manchester, UK – 8 January 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group...

Yourgene Health plc(“Yourgene”, the “Company” or the “Group”) Half-year Results Manchester, UK – 3 December 2018: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its unaudited...

Premaitha Health plc(“Premaitha” or the “Group”) Change of Name to Yourgene Health plc&Change of Website Address Manchester, UK – 7 November 2018: Premaitha Health plc, the international molecular diagnostics group which commercialises genetic products and...

Premaitha Health plc(“Premaitha” or the “Group”) Trading Update & Notice of Results Manchester, UK – 12 October 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to provide an update on trading for the...

Premaitha Health PLC(“Premaitha,” the “Company” or the “Group”) $1 million collaboration agreementPartnership to provide genetic testing based on next generation sequencing for oncology Manchester, UK – 4 October 2018: Premaitha (AIM: NIPT), a leading international...

THIS ANNOUNCEMENT, INCLUDING THE APPENDIX AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, THE REPUBLIC...

Premaitha Health PLC(“Premaitha,” the “Company” or the “Group”) Full year results to 31 March 2018 and half-year trading update Manchester, UK – 28 September 2018: Premaitha (AIM: NIPT), a leading international molecular diagnostics group, announces its full year...

Premaitha Health plc(“Premaitha” or the “Group”) Senior Commercial Appointment and Anticipated Directorate Change Manchester, UK – 20 September 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to announce the...

Premaitha Health plc(“Premaitha” or the “Group”) Legal Settlement and Licence Agreement with Illumina Manchester, UK – 19 September 2018: Premaitha Health plc (AIM: NIPT), a leading  international molecular diagnostics group, is pleased to announce that the Group...

Premaitha Health plc(“Premaitha” or the “Group”) Board Changes Manchester, UK – 4 July 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to announce the appointment of Mr Lyn Rees as Chief Executive Officer and Mr...

Premaitha Health plc(“Premaitha” or the “Company”) Collaboration with Abnova Partnership to develop next generation sequencing capability for single cell analysis Manchester, UK – 26 June 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular...

Premaitha Health plc(“Premaitha” or the “Company”) Premaitha wins ‘Outstanding NIPS Solution Provider of the Year’ award Manchester, UK – 13 June 2018: Premaitha Health plc (AIM:NIPT), a leading international molecular diagnostics group, is proud to announce that it...

Premaitha Health plc(“Premaitha” or the “Company”) Partnership agreement for DNA sequencing technology development Manchester, UK – 11 June 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, announces that it has signed an...

Premaitha Health plc(“Premaitha”, the “Company” or the “Group”) Premaitha signs NIPT partnership agreement in India Manchester, UK – 5 June 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal...

Premaitha Health plc(“Premaitha” or the “Company”) Premaitha expands footprint with new laboratories in Kenya and India Manchester, UK – 15 May 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal...

Premaitha Health plc (“Premaitha”, the “Company” or the “Group”) Year-end Trading Update and £2.5m Fundraising Revenues doubled in the year ended 31 March 2018 & An additional £2.5m funds raised Manchester, UK – 15 May 2018: Premaitha Health plc (AIM: NIPT), a...

Premaitha Health plc(“Premaitha” or the “Company”) Premaitha to attend key industry conferences in Asia Pacific Manchester, UK – 29 March 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused...

Premaitha Health plc(“Premaitha” or the “Company”) Update on UK patent infringement claim received in September 2017 Manchester, UK – 26 March 2018: Premaitha Health plc (AIM: NIPT), a leading international moleculardiagnostics group focused on non-invasive prenatal...

Premaitha Health plc(“Premaitha” or the “Company”) Premaitha secures market entry into Egypt Manchester, UK – 16 February 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”),...

Premaitha Health plc(“Premaitha” or the “Company”) Premaitha raises awareness of the IONA® test at key conferences in the Middle East Manchester, UK – 6 February 2018: Premaitha Health plc (AIM: NIPT), a leading international...

Premaitha Health plc(“Premaitha” or the “Company”) Premaitha’s IONA® test approved for sale in Brazil Manchester, UK – 5 February 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group...

Premaitha Health PLC(“Premaitha”, the “Company” or the “Group”)Half year resultsManchester, UK – 29 December 2017: Premaitha Health PLC (AIM: NIPT), a leading molecular diagnostics group with a primary focus on the...

Premaitha Health PLC(“Premaitha” or the “Company”) Premaitha secures four further laboratories in Europe Manchester, UK – 11 December 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on...

Premaitha CEO Wins Bionow Outstanding Contribution Award Manchester, UK – 1 December 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), is proud to announce that its CEO,...

Premaitha Health PLC(“Premaitha” or the “Company”) Middle East laboratory network expansion Manchester, UK – 27 November 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT),...

Premaitha Health plc(“Premaitha” or the “Company”) Premaitha signs new partner to offer NIPT solution in East Asia Manchester, UK – 23 November 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal...

Premaitha Health plc(“Premaitha” or the “Company” or the “Group”) Litigation First Instance Judgment Manchester, UK – 21 November 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing...

Premaitha Health PLC(“Premaitha” or the “Company”) Commercial progress in the Middle East Manchester, UK – 13 October 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces...

Issued on behalf of Premaitha Health plcManchester, UK: Friday, 29 Sept 2017 Premaitha Health PLC(“Premaitha,” the “Company” or the “Group”) Full year results to 31 March 2017 and half-year trading update Manchester, UK – 29 September 2017: Premaitha (AIM: NIPT), a...

Premaitha Health PLC(“Premaitha” or the “Company”) Premaitha to offer NIPT in South Africa Manchester, UK – 19 September 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing, announces...

Premaitha Health plc(“Premaitha” or the “Company”) Further patent infringement claims received from Illumina & Sequenom Manchester, UK – 7 September 2017: Premaitha Health plc (AIM: NIPT) announces that it has today received notification from Illumina and Sequenom...

Premaitha Health plc(“Premaitha” or the “Company”) Premaitha approved for Good Manufacturing Practice by ANVISA Brazil Manchester, UK – 29 August 2017: Premaitha Health plc (AIM: NIPT) announces that it has been approved for Brazilian Good Manufacturing Practice...

Premaitha Health Plc(“Premaitha”, the “Company” or the “Group”) Investment Agreement Extension with Thermo Fisher Scientific Manchester, UK – 12 July 2017 - Premaitha Health Plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive...

Premaitha Health plc(“Premaitha” or the “Company” or the “Group”) Premaitha announces two laboratory hub contracts in South East Asia Manchester, UK – 10 July 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on...

Premaitha Health PLC(“Premaitha” or the “Company”) Litigation Update Manchester, UK – 3 July 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), provides the following update on...

Premaitha Health PLC (“Premaitha” or the “Company”) The IONA® test updated to include the first trimester combined test result Manchester, UK – 26 June 2017: Premaitha Health, a leading international molecular diagnostics group focused on non-invasive prenatal testing...

Premaitha Health PLC(“Premaitha” or the “Company”) Premaitha launches Sage™ prenatal screening solution in Hong Kong Manchester, UK – 16 June 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal...

Premaitha Health plc(“Premaitha” or the “Company” or the “Group”) India Business Update Manchester, UK – 5 June 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing, is pleased to provide...

Premaitha Health PLC(“Premaitha” or the “Company”)   Premaitha completes IONA test validation on Thermo Fisher’s Ion S5 instrument   Manchester, UK – 26 May 2017: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), a leading international...

Premaitha Health PLC (“Premaitha” or the “Company”)   Premaitha welcomes NIPT recommendation in France   Haute Authorité de Santé recommends introduction of NIPT for high and intermediate risk women   Manchester, UK – 19 May 2017: Premaitha Health plc...

Premaitha Health PLC(“Premaitha” or the “Company”) Update Re. Swiss Customer Manchester, UK – 12 May 2017: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), a leading international molecular diagnostics group focused on prenatal testing, announces that...

Premaitha Health PLC(“Premaitha” or the “Company”) Premaitha Raises Awareness of the IONA® Test at Key International Medical Events Manchester, UK – 13 March 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular...

Premaitha Health PLC(“Premaitha” or the “Company” or the “Group”) Completion of Yourgene Acquisition, Issue of Shares and Director Appointments Manchester, UK – 27 February 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group...

Premaitha Health PLC(“Premaitha” or the “Company”) Middle East Business Update Manchester, UK – 20 February 2017: Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, is pleased to announce significant commercial...

Premaitha Health PLC(“Premaitha” or the “Company”) Publication of scientific paper on Premaitha’s IONA® test Manchester, UK – 16 February 2017: Premaitha Health, developer of a leading CE-marked non-invasive prenatal screening...

Premaitha Health plc("Premaitha" or the "Company") Issue of Equity Manchester, UK - 15 February 2017: Premaitha Health plc (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces that it has agreed to issue to Harwood Capital...

Premaitha Health PLC(“Premaitha” or the “Company”) New partnership with major European diagnostics group Manchester, UK – 13 February 2017: Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces a...

Premaitha Health PLC(“Premaitha” or the “Company”) Southern Europe Business Update Manchester, UK – 7 February 2017: Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces a number of new customers through...

Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 21 December 2016 Premaitha Health PLC (“Premaitha” or “the Company”) Half Year Results Manchester, UK – 21 December 2016: Premaitha Health (AIM: NIPT), developer of a leading CE-marked non-invasive...

Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 21 December 2016 Premaitha Health PLC(“Premaitha” or “the Company”) Conditional Acquisition of Yourgene Bioscience and Posting of Circular Manchester, UK – 21 December 2016: Premaitha Health PLC (AIM:...

Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 21 November 2016 Premaitha Health PLC(“Premaitha” or “the Company”) Premaitha establishes first service laboratory customer in Asia the IONA® test to be offered in the Center for Medical Genomics,...

Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 31 October 2016 Premaitha Health PLC(“Premaitha” or “the Company”) NHS to adopt NIPT for high risk women Premaitha welcomes UK Govt. decision Manchester, UK – 31...

Issued on behalf of Premaitha Health plcManchester, UK: Thursday, 27 Oct 2016 Premaitha Health Plc(“Premaitha” or the “Company”) AGM Statement Manchester, UK – 27 October 2016 – At the Annual General Meeting of Premaitha to be held...

Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 30 Sept 2016 Premaitha Health plc(“Premaitha” or the “Company”) Final results Manchester, UK – 30 September 2016 - Premaitha Health plc (AIM: NIPT), developer of the...

Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 23 September 2016 RNS Number : 6625KPremaitha Health PLC23 September 2016 Premaitha Health Plc ("Premaitha" or the "Company") Investment agreement extension with Thermo Fisher Scientific Manchester, UK -...

Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 4 July 2016 Progress on anti-trust objections to litigation Manchester, UK – 4 July 2016: Premaitha Health plc (AIM: NIPT), developer of the leading CE-marked complete non-invasive prenatal screening...

Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 27 June 2016 Launch of MyNIPT™ Online Portal for the IONA® test Manchester, UK – 27 June 2016 - Premaitha Health PLC (AIM: NIPT), developer of the IONA® test, the leading CE-marked complete non-invasive...

Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 22 April 2016 Premaitha Health plc(“Premaitha” or the “Company”)   Update on competitor patent litigation   Manchester, UK - 22 April 2016 - Premaitha Health PLC (AIM: NIPT, "Premaitha" or the...

Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 20 April 2016 Premaitha Health plc(“Premaitha” or the “Company”) Patent litigation rescheduled Manchester, UK – 20 April 2016: Premaitha Health plc (AIM: NIPT), developer of the leading CE-marked...

Issued on behalf of Premaitha Health plc Manchester, UK: Tuesday, 29 March 2016 Premaitha announces tenth customer laboratory Manchester, UK – 29 March 2016: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), announces that its French distributor,...

Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 21 March 2016 Premaitha Enters Middle East with Series of Regional Laboratory Hubs   Manchester, UK – 21 March 2016: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), developer of the...

Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 11 March 2016 Premaitha Health plc(“Premaitha” or the “Company”) Premaitha wins at North West Business Masters Awards 2016 Manchester, UK – 11 March 2016: Premaitha Health plc (AIM: NIPT), the company...

Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 9 March 2016 Premaitha Health plc(“Premaitha” or the “Company”) Premaitha signs distribution agreement with GeNext in Russia Manchester, UK – 9 March 2016: Premaitha Health plc (AIM: NIPT), the...

Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 3 February 2016 Premaitha Health partners with Visional Medical to provide the IONA® test to pregnant women in India Manchester, UK and Chennai, India – 3 February 2016 – Premaitha Health plc (AIM:...

Issued on behalf of Premaitha Health plc Manchester, UK: Tuesday, 2 February 2016 Premaitha Health partners with Leeds Teaching Hospitals NHS Trust to offer pregnant women safer non-invasive prenatal screening service Manchester and Leeds, UK – 2 February 2016 –...

Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 27 January 2016 Premaitha Health signs two new customers for its clinical laboratory NIPT screening service Manchester, UK – 27 January 2016 – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the...

Issued on behalf of Premaitha Health plc Manchester, UK: Tuesday, 26 January 2016 Update on UK Litigation Timing Manchester, UK – 26 January 2016: Premaitha Health PLC (“Premaitha” or “the Company”; AIM: NIPT) provides investors with visibility of the timelines...

Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 15 January 2016 Premaitha Health welcomes recommendation for NHS provision of non-invasive prenatal testing National Screening Committee recommendation will enable more pregnant women to benefit from...

Manchester, UK – 8 January 2016 – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”), developer of the IONA® test, the first CE-marked non-invasive prenatal (NIPT) in vitro diagnostic kit, notes that Illumina, Inc. has today announced two patent...

Issued on behalf of Premaitha Health plc Manchester, UK: Tuesday, 5 January 2016 Premaitha Health launches Workflow Manager system for the IONA® test to support clinical laboratory customers Comprehensive clinical sample and patient data tracking from receipt to...

Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 14 December 2015 Results for the half year ended 30 September 2015 Manchester, UK – 14 December 2015: Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”)...

Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 14 December 2015 Premaitha Health signs Investment Agreement with Thermo Fisher Scientific Manchester, UK – 14 December 2015: Premaitha Health PLC (AIM: NIPT, “Premaitha” or the...

Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 2 December 2015 Premaitha establishes the first IONA® testing service in France at LaboSud Manchester, UK and Montpellier, France – 2 December 2015 – Premaitha Health plc (AIM: NIPT, “Premaitha” or...

Issued on behalf of Premaitha Health plc Manchester, UK: Thursday, 12 November 2015 Independent, multi-centre clinical study of the IONA® test in high risk pregnancies shows 100% detection of trisomies and 0% false positives Study verifies performance of the test and...

Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 14 October Premaitha opens dedicated clinical laboratory with expanded capacity to meet demand for IONA® test service Manchester, UK – 14 October 2015 – Premaitha Health plc (AIM:...

Issued on behalf of Premaitha Health plc Manchester, UK: Tuesday, 13 October 2015 RNS 7.00am Tuesday 13th October 2015 In-house Antenatal reflex DNA screening for Down’s syndrome, trisomy 18 and trisomy 13: a world first The Wolfson Institute of Preventive Medicine...

Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 12 October 2015 Independent performance study of the IONA® test published Further verification of the test showing 100% of trisomies detected and 0% false positives from 242 maternal blood samples...

Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 2 October 2015 Premaitha appoints Antisel SA to distribute the IONA® test in Greece Manchester, UK and Athens, Greece – 2 October 2015 – Premaitha Health plc (“Premaitha” or “the Company”, AIM: NIPT),...

Issued on behalf of Premaitha Health plc Manchester, UK: Thursday, 1 October 2015 Illumina Patent Infringement Proceedings Update Manchester, UK – 1 October 2015 - Premaitha Health plc ("Premaitha" AIM: NIPT) an innovative molecular diagnostics company employing the...

Issued on behalf of Premaitha Health plc Manchester, UK: Tuesday, 22 September 2015 Premaitha signs first non-European partnership with Servicios Genéticos OriGen to provide the IONA® test for pregnant women in Chile Manchester, UK and Santiago, Chile – 22 September...

Issued on behalf of Premaitha Health plc Manchester, UK: Thursday, 2 July 2 July 2015Premaitha Health plc (“Premaitha” or the “Company”) Completion of placing to raise £8 million Premaitha (AIM: NIPT) has successfully completed the...

Not for publication, distribution or release directly or indirectly, in whole or in part, in or into the United States, Canada, Australia, New Zealand, Japan, the Republic of Ireland or the Republic of South Africa or in any other jurisdiction in which offers or sales...

Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 24 June 2015     New IONA® test clinical data showcased at the World Congress in Fetal Medicine Manchester, UK - 24 June 2015 – Premaitha Health plc (“Premaitha” or “the Company”, AIM:...

Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 22 June 2015 New contract for IONA® test Manchester and Leeds, UK – 22 June 2015 – Premaitha Health plc (“Premaitha” or “the Company”, AIM: NIPT), developer of the IONA® test, the first CE-marked test...

Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 15 June 2015 Clinical and performance data from the IONA® test to be presented at the World Congress in Fetal Medicine, Crete Manchester, UK 15 June 2015 – Premaitha Health plc (“Premaitha”, AIM: NIPT)...

Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 6 July 2015 Premaitha Health receives CQC accreditation for new NIPT clinical service laboratory to support IONA® test customers Manchester, UK – 6 July 2015 – Premaitha Health plc (“Premaitha” or “the...

Issued on behalf of Premaitha Health plc Manchester, UK: Thursday, 4 June 2015 Directorate Change Manchester, UK – 4 June 2015: Premaitha Health plc (“Premaitha” or “the Company”; AIM: NIPT) announces the appointment of Barry Hextall, CGMA, MBA, CertIOD as Chief...

Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 22 May 2015 Premaitha Health wins Medical & Lifescience Award at Insider’s Made in the North West Awards Manchester, UK – 22 May 2015 – Premaitha Health plc (“Premaitha”, AIM: NIPT) has been awarded...

Issued on behalf of Premaitha Health plc Manchester, UK: Tuesday, 5 May 2015 Premaitha files robust defence with UK’s High Court in response to alleged infringement of NIPT patents Manchester, UK – 5 May 2015 – Premaitha Health plc (“Premaitha”, AIM: NIPT) announces...

The two companies will work closely together as they establish Centrum Badan as Premaitha’s preferred partner laboratory within Poland.  

The IONA® test is the first CE-marked in vitro diagnostic (IVD) product for NIPT, enabling genetic laboratories such as Centrum Badan to offer NIPT in-house. It uses next-generation sequencing (NGS) technology to estimate the risk of a fetus having serious genetic disorders such as Down’s syndrome (Trisomy 21), Edwards’ syndrome (Trisomy 18) and Patau’s syndrome (Trisomy 13) by analysing cell-free fetal DNA from a sample of maternal blood. The IONA test® has a higher detection rate and lower false positive rate than the current combined test available to pregnant women in Poland.  

Issued on behalf of Premaitha Health plc and St George’s University Hospitals NHS Foundation Trust Manchester, UK and London, UK: Monday, 23 March 2015 Leading London NHS trust teams up with Premaitha Health to create the UK’s first Centre of Excellence for...

Issued on behalf of Premaitha Health plc and Esperite NV Manchester, UK and Zutphen, The Netherlands: Monday, 16 March 2015 Premaitha Health and Esperite NV sign a collaboration agreement for NIPT provision in Europe Manchester, UK and Zutphen, the Netherlands – 16...

Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 16 March 2015 PRESS RELEASE Notice of Patent Infringement Proceedings Manchester, UK – 16 March 2015 – Premaitha Health plc (“Premaitha” AIM: NIPT) an innovative molecular diagnostics company employing...

Issued on behalf of Premaitha Health plc Manchester, UK: Thursday, 5 February 2015 Premaitha Health plc (“Premaitha” or the “Company”, AIM: NIPT), an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for...

Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 30 January 2015 Achieves significant milestones in preparing for CE-mark and commercial launch Premaitha Health plc (”Premaitha” or the “Company”, AIM: NIPT), an innovative molecular diagnostics company...

Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 28 November 2014 £7.2m reverse listing to AIM enabling commercialisation of ground-breaking test for Down’s syndrome Manchester, UK – 28 November 2014 – Premaitha Health (‘Premaitha’) (AIM: NIPT), an...

Issued on behalf of Premaitha Health plc Manchester, UK: Thursday, 6 November 2014 Premaitha Health (‘Premaitha’) (AIM: NIPT), an innovative molecular diagnostics company bringing advantages in Next Generation DNA sequencing to non-invasive prenatal testing (NIPT),...

Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 4 July 2014 The Premaitha business Today, Premaitha, located at the Manchester Science Park, UK has commenced trading on London Stock Exchange platform AIM. The Company has raised £7.2m by way of Placing...

UK: Friday 13 June 2014: Molecular Diagnostics Company, Premaitha Health, based in Manchester’s Science Technology Park announces today that it has agreed terms to join ViaLogy plc, an investment company quoted on the London Stock Exchange. Subject to ViaLogy...